Sugi Predict

Sugi Predict / Compounds / SCHEMBL1920132

SCHEMBL1920132

SCHEMBL1920132

CC(C)(C)C1C(N)CCCN1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 9/20 0.40
▸ HSD17B10 Q99714 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ FAP Q12884 6/20 0.37
▸ DPP8 Q6V1X1 5/20 0.37
▸ DPP9 Q86TI2 5/20 0.37
▸ DPP7 Q9UHL4 5/20 0.37
▸ RIPK1 Q13546 1/20 0.37
▸ PITRM1 Q5JRX3 1/20 0.36
▸ PREP P48147 3/20 0.33
▸ POLB P06746 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14480015 1.00 DPP4 (0.40) DPP4HSD17B10LMNACYP2C19FAP
SCHEMBL5002190 1.00 DPP4 (0.40) DPP4HSD17B10LMNACYP2C19FAP
SCHEMBL2430899 1.00 DPP4 (0.40) DPP4HSD17B10LMNACYP2C19FAP
SCHEMBL2330612 0.95 HPGD (0.38) DPP4HSD17B10LMNACYP2C19FAP
SCHEMBL16600622 0.89 DPP4 (0.34) DPP4HSD17B10LMNACYP2C19RIPK1
SCHEMBL322779 0.89 DPP4 (0.34) DPP4HSD17B10LMNACYP2C19RIPK1
SCHEMBL4523902 0.89 DPP4 (0.34) DPP4HSD17B10LMNACYP2C19RIPK1
SCHEMBL322778 0.89 DPP4 (0.34) DPP4HSD17B10LMNACYP2C19RIPK1
Hydrochloric Acid SCHEMBL7517295 0.87 DPP4 (0.33) DPP4LMNARIPK1
SCHEMBL29392820 0.85 DPP4 (0.40) DPP4HSD17B10LMNACYP2C19FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4656249-A2 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR Daewoong Pharmaceutical Co., Ltd. (KR) 2025-12-03 — — EP disclosed
EP-4562011-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF Zymeworks BC Inc. (CA) 2025-06-04 — — EP disclosed
US-20250170266-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF ZYMEWORKS BC INC. (CA) 2025-05-29 — — US disclosed
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
EP-3478687-B1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR DAEWOONG PHARMACEUTICAL CO LTD (KR) 2024-03-20 — — EP disclosed
WO-2024020684-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF ZYMEWORKS BC INC. (CA) 2024-02-01 — — WO disclosed
WO-2023204642-A1 PROTEIN KINASE INHIBITOR AND USE THEREOF (주)메디톡스 2023-10-26 — — WO disclosed
CN-116406272-A DNA-PK selective inhibitor and preparation method and application thereof 首药控股(北京)股份有限公司 2023-07-07 — — CN disclosed
CN-114605414-A DNA-PK selective inhibitor and preparation method and application thereof 首药控股(北京)股份有限公司 2022-06-10 — — CN disclosed
EP-3950691-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR Daewoong Pharmaceutical Co., Ltd. (KR) 2022-02-09 — — EP disclosed
EP-2326639-A1 SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2011-06-01 — — EP disclosed
EP-2229392-A1 TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE AS GSK3BETA INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2010-09-22 — — EP disclosed
EP-2176264-A1 IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE Bayer Schering Pharma AG (DE) 2010-04-21 — — EP disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 — — EP disclosed
WO-2010012398-A1 SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-02-04 — — WO disclosed
EP-2137188-A2 SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES Bayer Schering Pharma Aktiengesellschaft (DE) 2009-12-30 — — EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 — — US disclosed
WO-2009074259-A1 TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-06-18 — — WO disclosed
WO-2009007029-A1 IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 — — WO disclosed
WO-2008113469-A2 SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 DPP4 4358/4885HSD17B10 3155/4885LMNA 1281/4885
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 DPP4 4446/4885HSD17B10 1069/4885LMNA 486/4885
US-20250170266-A1 IMMUNOMODULATOR PURINE-DERIVED COMPOUNDS, CONJUGATES THEREOF, AND METHODS OF USE THEREOF PAICS, ENTPD5, PNP DPP4 1954/4885HSD17B10 4370/4885LMNA 3967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.